Clinical Trials Logo

Carcinoid Tumor of GI System clinical trials

View clinical trials related to Carcinoid Tumor of GI System.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04197310 Completed - Clinical trials for Neuroendocrine Tumors

Cabozantinib and Nivolumab for Carcinoid Tumors

Start date: December 26, 2019
Phase: Phase 2
Study type: Interventional

This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. - Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.

NCT ID: NCT03722511 Completed - Diarrhea Clinical Trials

Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

Start date: December 6, 2018
Phase: Phase 2
Study type: Interventional

Primary Objective: To assess how an amino acid based medical food (Enterade®) helps maintain the intestine's ability to absorb and retain fluids, leading to a reduction in diarrhea due to Neuroendocrine Tumors (NET) and/or Carcinoid Syndrome. This improvement in the absorption will be assessed in part by evaluating changes in average daily stool frequency from baseline in patients receiving Enterade®. Each subject serves as his or her own control. Secondary Objectives: - To assess subject reported health-related quality of life in subjects before and after compound administration. - To characterize the side effect profile and tolerability of Enterade® as measured by the number of total 8-oz Enterade® bottles consumed throughout the trial, and average drinks per day. - To evaluate changes in serum electrolytes before and after administration of Eenterade®. - To assess intravenous fluid requirement and/or hospitalization for dehydration secondary to diarrhea between control observation period and active Enterade® period. - To evaluate difference in utilization of standard-of-care anti-diarrheal medications between control observation period and Enterade® period. - To compare subjective feeling of bloating and flatulence before and after administration of Enterade®. - To evaluate changes in patient weight before and after administration of Enterade®.